Risk factors for proven or probable IA among case (n = 187) and control (n = 1495) patients who received allogeneic HSCTs at FHCRC, 1993-1998
| . | Controls, no. (%) . | Cases, no. (%) . | HR . | 95% CI . |
|---|---|---|---|---|
| Recipient-related factors | ||||
| Age, y | ||||
| Younger than 19 | 239 (16.0) | 23 (12.3) | 1.0 | — |
| 19-40 | 634 (42.4) | 67 (35.8) | 1.5 | NS |
| Older than 40 | 622 (41.6) | 97 (51.9) | 2.4 | 1.5-3.82-153 |
| Underlying disease | ||||
| CML, chronic phase | 367 (24.6) | 37 (19.8) | 1.0 | — |
| Hematologic malignancy, first remission | 151 (10.1) | 15 (8.0) | 1.1 | NS |
| Hematologic malignancy, other | 650 (43.5) | 79 (42.3) | 1.6 | 1.1-2.42-155 |
| Other* | 327 (21.9) | 56 (30.0) | 2.1 | 1.4-3.22-153 |
| Transplant-related factors (donor and stem cell source) | ||||
| MR BM | 509 (34.1) | 57 (30.5) | 1.0 | — |
| MR PBSCs | 175 (11.7) | 17 (9.1) | 0.7 | NS |
| MM/UR BM | 779 (52.1) | 103 (55.1) | 1.1 | NS |
| MM/UR PBSCs | 22 (1.5) | 7 (3.7) | 2.8 | 1.1-7.02-155 |
| Cord blood | 10 (0.7) | 3 (1.6) | 5.1 | 1.5-17.22-155 |
| T cell–depleted/CD34-selected | 54 (3.6) | 16 (8.6) | 2.2 | 1.2-4.12-155 |
| Transplant complications | ||||
| Neutropenia† | — | — | 3.0 | 2.0-4.62-153 |
| GVHD, acute†,‡ | ||||
| Grades 0-1 | — | — | 1.0 | |
| Grades 2-4 | 2.2 | 1.4-3.42-153 | ||
| Missing | 2.1 | NS | ||
| GVHD, chronic (clinically extensive)†,‡ | — | — | 2.2 | 1.3-3.72-155 |
| CMV disease† | — | — | 7.0 | 4.5-10.82-153 |
| Respiratory virus infection† | — | — | 2.1 | 1.4-3.12-153 |
| . | Controls, no. (%) . | Cases, no. (%) . | HR . | 95% CI . |
|---|---|---|---|---|
| Recipient-related factors | ||||
| Age, y | ||||
| Younger than 19 | 239 (16.0) | 23 (12.3) | 1.0 | — |
| 19-40 | 634 (42.4) | 67 (35.8) | 1.5 | NS |
| Older than 40 | 622 (41.6) | 97 (51.9) | 2.4 | 1.5-3.82-153 |
| Underlying disease | ||||
| CML, chronic phase | 367 (24.6) | 37 (19.8) | 1.0 | — |
| Hematologic malignancy, first remission | 151 (10.1) | 15 (8.0) | 1.1 | NS |
| Hematologic malignancy, other | 650 (43.5) | 79 (42.3) | 1.6 | 1.1-2.42-155 |
| Other* | 327 (21.9) | 56 (30.0) | 2.1 | 1.4-3.22-153 |
| Transplant-related factors (donor and stem cell source) | ||||
| MR BM | 509 (34.1) | 57 (30.5) | 1.0 | — |
| MR PBSCs | 175 (11.7) | 17 (9.1) | 0.7 | NS |
| MM/UR BM | 779 (52.1) | 103 (55.1) | 1.1 | NS |
| MM/UR PBSCs | 22 (1.5) | 7 (3.7) | 2.8 | 1.1-7.02-155 |
| Cord blood | 10 (0.7) | 3 (1.6) | 5.1 | 1.5-17.22-155 |
| T cell–depleted/CD34-selected | 54 (3.6) | 16 (8.6) | 2.2 | 1.2-4.12-155 |
| Transplant complications | ||||
| Neutropenia† | — | — | 3.0 | 2.0-4.62-153 |
| GVHD, acute†,‡ | ||||
| Grades 0-1 | — | — | 1.0 | |
| Grades 2-4 | 2.2 | 1.4-3.42-153 | ||
| Missing | 2.1 | NS | ||
| GVHD, chronic (clinically extensive)†,‡ | — | — | 2.2 | 1.3-3.72-155 |
| CMV disease† | — | — | 7.0 | 4.5-10.82-153 |
| Respiratory virus infection† | — | — | 2.1 | 1.4-3.12-153 |
Hazard ratios (HRs) and 95% confidence intervals (CIs) are shown for all significant variables.
—indicates data not applicable; NS, not significant in the multivariable model.
The most common “other” diagnoses are aplastic anemia, myelodysplastic syndrome, and multiple myeloma.
Factors entered into the model as time-dependent covariates.
The GVHD variable “missing” signifies patients who did not have data entered into the computerized system (n = 118). Acute and chronic GVHD were independently graded, as previously described.17 18
P ≤ .001.
P ≤ .05.